SEARCH

SEARCH BY CITATION

References

  • 1
    Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 19211926.
  • 2
    Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, et al. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. HEPATOLOGY 1999; 29: 13061310.
  • 3
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 4
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 6168.
  • 5
    Cooper D, Cheng A, Coakley D, Sayre J, Zhong L, Chen S, et al. Anti-HBV activity of tenofovir disoproxil fumarate (TDF) in lamivudine experienced HIV/HBV co-infected [Abstract]. In: Ninth Conference on Retroviruses and Opportunistic Infection; February 24–28, 2002; Seattle, WA. Abstract p. 124.
  • 6
    Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals. AIDS 2003; 17: F7F10.
  • 7
    de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, et al. Safety and effectiveness of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. HEPATOLOGY 2001; 34: 578582.
  • 8
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333: 16571661.
  • 9
    Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N, et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996; 125: 705712.
  • 10
    Dore G, Cooper D, Barrett C, Goh L, Thakrar B, Atkins M, et al. Dual effectiveness of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). J Infect Dis 1999; 180: 607613.
  • 11
    Benhamou Y, Bochet M, Thibault V, Di Martino V, Caumes E, Bricaire F, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. HEPATOLOGY 1999; 30: 13021306.
  • 12
    Pillay D, Cane P, Ratcliffe D, Atkins M, Cooper D. Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. AIDS 2000; 14: 11111116.
  • 13
    Cooley L, Ayers A, Bartholomeusz A, Lewin S, Crowe S, Mijch A, et al. Prevalence and characterisation of lamivudine-resistant Hepatitis B virus (HBV) mutations in HIV and HBV co-infected individuals. AIDS 2003; 27: 16491657.
  • 14
    Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863870.
  • 15
    Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9: 8288.
  • 16
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretrovirals in HIV-1-infected adults and adolescents; November 3, 2008. Department of Health and Human Services: Washington, DC; http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 2008.
  • 17
    Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 1996; 93: 43984402.
  • 18
    Lau GK, Tsiang M, Hou J, Yuen S, Carman WF, Zhang L, et al. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. HEPATOLOGY 2000; 32: 394399.
  • 19
    Lewin S, Ribeiro R, Walters T, Lau G, Bowden S, Locarnini S, et al. Analysis of hepatitis B viral load decline under potent therapy: complex decay profiles observed. HEPATOLOGY 2001; 34: 10121020.
  • 20
    Tsiang M, Rooney JF, Toole JJ, Gibbs CS. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy. HEPATOLOGY 1999; 29: 18631869.
  • 21
    Chang J, Wightman F, Bartholomeusz A, Ayres A, Kent S, Sasadeusz J, et al. Reduced HBV-specific CD4+ T-cell responses in HIV-1-HBV co-infected individuals receiving HBV-active antiretroviral therapy. J Virol 2005; 79: 30383051.
  • 22
    Lascar RM, Gilson RJ, Lopes AR, Bertoletti A, Maini MK. Reconstitution of hepatitis B virus (HBV)-specific T cell responses with treatment of human immunodeficiency virus/HBV coinfection. J Infect Dis 2003; 188: 18151819.
  • 23
    Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al. Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection. J Infect Dis 2003; 188: 14981507.
  • 24
    Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. HEPATOLOGY 2006; 43: 943953.
  • 25
    Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naive individuals in Thailand. HEPATOLOGY 2008; 48: 10621069.
  • 26
    Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004; 95: 125149.
  • 27
    Werle B, Wursthorn K, Petersen J, Bowden S, Locarnini S, Lau G, et al. Quantitative analyses of hepatic HBV ccc DNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy: an International, Multicenter study [Abstract]. HEPATOLOGY 2002; 36(Suppl): 296A.
  • 28
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral effectiveness of interferon-alpha therapy. Science 1998; 282: 103107.
  • 29
    Milich D, Chen M, Hughes J, Jones J. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 20132021.
  • 30
    Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. HEPATOLOGY 2007; 45: 102110.
  • 31
    Wolters LM, Hansen BE, Niesters HG, DeHertogh D, de Man RA. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol 2002; 37: 137144.
  • 32
    Wang CC, Holte S, Huang ML, Sacks SL, Engelberg R, Ferrenberg J, et al. Kinetics of hepatitis B viral load during 48 weeks of treatment with 600 mg vs 100 mg of lamivudine daily. J Viral Hepat 2004; 11: 443447.
  • 33
    Dienstag J. Hepatitis B virus infection. N Engl J Med 2008; 359: 14861500.
  • 34
    Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti-hepatitis B virus effectiveness of tenofovir disoproxil fumarate in HIV-infected patients. HEPATOLOGY 2006; 43: 548555.
  • 35
    Audsley J, Arrifin N, Yuen L, Ayres A, Crowe S, Bartholomeusz A, et al. Prolonged use of Tenofovir in HIV-HBV co-infected individuals does not lead to HBV polymerase mutations and is associated with persistence of Lamivudine HBV polymerase mutations. HIV Med. In press.
  • 36
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Effectiveness of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 11851192.
  • 37
    Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48: 728735.
  • 38
    Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther 2007; 12: 705718.
  • 39
    Hui CK, Zhang HY, Bowden S, Locarnini S, Luk JM, Leung KW, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48: 714720.
  • 40
    Colombatto P, Civitano L, Bizzarri R, Oliveri F, Choudhury S, Gieschke R, et al. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy. Antivir Ther 2006; 11: 197212.
  • 41
    Sypsa VA, Mimidis K, Tassopoulos NC, Chrysagis D, Vassiliadis T, Moulakakis A, et al. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. HEPATOLOGY 2005; 42: 7785.
  • 42
    Ribeiro R, Germanidis G, Powers K, Pellegrin B, Perelson A, Pawlotsky J. HBV viral kinetics under antiviral therapy help understand the anti-HBV immune response in HBeAg-negative patients with chronic hepatitis B [Abstract]. HEPATOLOGY 2005; 42(Suppl): 721A.
  • 43
    Fang CT, Chen PJ, Chen MY, Hung CC, Chang SC, Chang AL, et al. Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection. J Hepatol 2003; 39: 10281035.
  • 44
    de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus AD, de Man RA, van der Ende ME. Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients. J Clin Virol 2006; 36: 6063.
  • 45
    van der Eijk AA, Hansen BE, Niesters HG, Janssen HL, van de Ende M, Schalm SW, et al. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants. J Viral Hepat 2005; 12: 364372.
  • 46
    Heathcote E, Gane E, DeMan R. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-0103. In: 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2007); November 2–6, 2007; Boston, MA.
  • 47
    Marcellin P, Buti M, Krastev Z, Germanidis G, Kaita K, Kotzev I, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): study GS-US-174-0102. In: 58th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2007); November 2–6, 2007; Boston, MA.
  • 48
    Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. HEPATOLOGY 2008; 47: 428434.